U.S. Markets closed

Pernix Therapeutics Holdings, Inc. (PTX)

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Add to watchlist
4.62+0.17 (+3.82%)
At close: 4:00PM EDT

4.90 0.28 (6.06%)
After hours: 5:08PM EDT

People also watch
  • Close green today, yeah!
  • This is just a finding.
  • Why up today ?
  • +7.46% after hours!
  • Did anyone else see $PTX report from http://squeezereport.com/?s=PTX ? It had some interesting information. Investing trading stocks. "rht"

  • Good news coming!
  • I smell 5.5$ before friday!
  • Another 5% today would be great. No bank offers me such a high rate!
  • Amazon is buying Whole Foods. All the market will be green today!
  • The positive attracts the positive!
  • Yes we can!
  • 5$ today!
  • Common PTX, you are a winner!
  • missed to buy it when it dropped below $4, PTX was in my radar for short, missed the opportunity to make a profit. Almost two months for that BO rumor?? I guess when it expired it would fall?? Their revenue seems to be decreasing in the past 3 quarters.
  • Every day I win 5% more on my starting bet! Coool
  • Hum,someone wants to raise the price. Again $ 7! I bought it at $4.20
  • IGXT (MC $46 M) US-NDA Submission for BLOCKBUSTER Drug this month =1000% Upside Potential ! PLEASE READ THIS

    2 US-NDA submission within 2 months ,lot of Cash and heavily underpriced at $46 million valuation .Load up guys before she the MEGA news hit the wire.Thank me later

    Intelgenx (IGXT)

    MarketCap $46 Million
    Cash untill 2021+ (including convertible debt)
    Price: 0.70

    NDA submission for tadalafil (erectile dysfunction) in June or July
    NDA resubmission for Rizaport (migraine) in early Q3
    Partnership for Tadalafil in 2H 2017


    IntelGenx previously confirmed the bioequivalence of Tadalafil to Eli Lilly’s Cialis, which had sales of $1.5-billion in 2016 but faces generic competition in 2020. IntelGenx has an exclusive license for oral films from Lilly for its dosing patent, which would allow Tadalafil to enter the ED market in the U.S. free from patent litigation from Lilly. Dr. Matzen explains that Tadalafil, which offers a discrete dosing alternative, could enter the market in 2018, with up to three years of market exclusivity before Cialis is hit with generic competition.

    IntelGenx has multi-faceted BD approach for its oral films
    With a burgeoning pipeline of pharmaceutical oral films, IntelGenx’s (OTCQX:IGXT; TSXV:IGX) business development strategy is focused on partnering its product pipeline along with actively meeting with potential partners to explore manufacturing
  • MonsterMicroCap Alert to PTX shareholders. BioLargo, Inc. (BLGO) on track to be enormous winner in 2017. Company is executing flawlessly and rapidly gaining industrial odor control sales with giant users. Sales just starting and expect parabolic growth curve leading to billion dollar sales.

    BLGO also filing 510k in July for new low cost, disruptive wound care products in a 6 billion dollar market. Expect sales to commence in near future leading to billion dollar sales.

    With highly disruptive, low cost water and air treatment solutions, and low cost advanced wound care products, BioLargo strongly positioned for monster growth.


    Biolargo's Odor-No-More to Revolutionize Waste Handling Industry with Industrial Odor Control Product - CupriDyne(R) Clean
    "Finally an Industrial Odor Control Product that Actually Works" DENVER, CO / ACCESSWIRE / June 6, 2017 / Anyone who's taken the trash out to the garbage cans knows that trash smells. And, we're ...
  • My target price to buy share is $3.5, not more. If not so be it!
  • What's behind the AH jump?